Shanghai Medicilon Inc.

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

  Cell & gene therapy has developed by leaps and bounds in recent years, providing the possibility for many refractory diseases.  With the rapid development of gene transduction and modification technology, delivery vector system, cell culture technology and other technology, breakthroughs have been made in cell & gene therapy, providing a new treatment concept and train of thoughts. Medicilon's preclinical research services cover pharmacodynamic research,  drug safety evaluation , pharmacokinetic research, bioanalysis, etc.  The establishment of a complete gene therapy R&D platform can provide one-stop services for research on pharmacological efficacy, biodistribution and safety evaluation of cell and gene therapy products. Medicilon has established a one-stop research platform for the preclinical research and development of cellular immunotherapy drugs, covering a variety of immunotherapy methods including CAR-T, TCR-T, CAR-NK and TIL cells, etc.  ...